Ossina

Ossianix is a privately held biotechnology company specializing in the development of a novel class of biologics derived from the variable regions of shark heavy-chain-only antibodies, known as VNARs. The company's proprietary platform focuses on engineering these small, stable, and highly specific molecules to cross the blood-brain barrier (BBB) by targeting the transferrin receptor. This technology enables the delivery of therapeutic payloads, including antibodies and enzymes, into the central nervous system to treat neurodegenerative and metabolic diseases. Ossianix has established significant research collaborations with major pharmaceutical companies to leverage its BBB-shuttle technology for various CNS indications.